Impact of minimed780G insulin pump therapy on quality of life in children and adolescents with type 1 diabetes: A comparative analysis

Abstract

The prevalence of type 1 diabetes mellitus (T1DM) among children is increasing. Advances in diabetes technology offer improved glycemic control while reducing the risks of hypoglycemia, hyperglycemia, and long-term complications. The MiniMed 780G, an Advanced Hybrid Closed Loop (AHCL) insulin delivery system, represents a significant improvement over traditional multiple daily injection (MDI) therapy. This prospective cohort study assessed the quality of life in 48 pediatric T1DM patients using either the MiniMed 780G or MDI, all monitored at the Endocrinology Outpatient Clinic of Military Hospitals. Participants were divided into two groups: 32 using MDI and 16 using the AHCL system. A structured questionnaire evaluated various aspects of treatment satisfaction. Results indicated that patients on the MiniMed 780G reported significantly higher satisfaction in areas such as diabetes management time, checkup duration, glucose monitoring ease, dietary flexibility, sleep quality, social interactions, academic and household engagement, and leisure activities (P < 0.05). Moreover, these patients experienced less pain, improved self-esteem, and reduced anxiety about complications, appearance, and hypoglycemic episodes compared to the MDI group, with all differences being statistically significant.